Search

Your search keyword '"Masquelier B"' showing total 322 results

Search Constraints

Start Over You searched for: Author "Masquelier B" Remove constraint Author: "Masquelier B"
322 results on '"Masquelier B"'

Search Results

1. Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants

2. Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course

3. Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy

6. HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes

7. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies

8. Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity

9. Virological failure of patients on maraviroc-based antiretroviral therapy

10. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

11. Isometric Strengh Database for Muscle Maximal Voluntary Endurance Field Tests:Normative Data

15. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001–2011

17. Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism

18. Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy

19. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France

22. Differences in the epidemiology of out-of-hospital and in-hospital trauma deaths

23. Snow avalanche deaths in Switzerland from 1995 to 2014—Results of a nation-wide linkage study

26. Health and mortality in francophone Africa

28. HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes

29. Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes

30. Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type I variants

31. Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants

33. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

34. Improving survey data on pregnancy-related deaths in low-and middle-income countries : a validation study in Senegal

35. Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type I variants

36. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

37. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

38. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

39. Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants

40. The Future Mortality of High Mortality Countries: A Model Incorporating Expert Arguments

41. Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts

42. Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes

43. Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing

44. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study

45. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe

46. Risk of triple-class virological failure in children with HIV: a retrospective cohort study

47. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis

48. Impact of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy – a European multi-cohort study – The EuroCoord-CHAIN joint project

49. European guidelines on the clinical management of HIV-1 tropism testing

50. European guidelines on the clinical management of HIV-1 tropism testing

Catalog

Books, media, physical & digital resources